# Akeso

Source: https://onco.cc/companies/akeso/  
OnCo record `akeso` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Chinese biotech whose ivonescimab beat Keytruda head-to-head, and developer of the Nectin-4×TROP2 ADC.

## Summary

Akeso, based in Zhongshan and listed in Hong Kong as 9926.HK, is the Chinese biotechnology company whose ivonescimab beat pembrolizumab head to head in the HARMONi-2 trial, and the developer of the Nectin-4 by TROP2 bispecific ADC AK146D1. Its portfolio includes ivonescimab, a PD-1 by VEGF bispecific, cadonilimab, a PD-1 by CTLA-4 bispecific proved in COMPASSION-16 in cervical cancer, and penpulimab, with Michelle Xia, Caicun Zhou and Wenfeng Fang among the people linked. OnCo connects it to lung, cervical and nasopharyngeal cancer, to HARMONi-A, to the bispecific ADC technology and to the NMPA, and to bottlenecks on regulatory divergence and trials that do not represent the people who get cancer. Whether the HARMONi-2 result holds in global trials run by its partner Summit is the open question. Ivonescimab has its own page.

## Fields

- Kind: Company
- Last checked: 2026-09-04
- HQ: Zhongshan
- Type: biotech
- Website: https://www.akesobio.com
- Ticker: 9926.HK

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Akeso
- Official website: https://www.akesobio.com

## Connected records

- fronts: [Antibody-Drug Conjugates](https://onco.cc/fronts/adcs/), [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- drugs: [AK117](https://onco.cc/drugs/ak117/), [AK119](https://onco.cc/drugs/ak119/), [AK146D1](https://onco.cc/drugs/ak146d1/), [Cadonilimab](https://onco.cc/drugs/cadonilimab/), [Ivonescimab](https://onco.cc/drugs/ivonescimab/), [Penpulimab](https://onco.cc/drugs/penpulimab/)
- trials: [A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)](https://onco.cc/trials/nct06601335/), [A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct05951608/), [A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer](https://onco.cc/trials/nct05846867/), [A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors](https://onco.cc/trials/nct05229497/), [A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.](https://onco.cc/trials/nct07052253/), [A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer](https://onco.cc/trials/nct07591090/), [A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07669779/), [A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma](https://onco.cc/trials/nct07023315/), [A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection](https://onco.cc/trials/nct05489289/), [A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer](https://onco.cc/trials/nct06953999/), [A Phase ll Study of Neoadjuvant Short-course Radiotherapy Followed by Ivonescimab and Chemotherapy in pMMR/MSS Locally Advanced Rectal Cancer](https://onco.cc/trials/nct06919510/), [A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC](https://onco.cc/trials/nct06617416/), [A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer](https://onco.cc/trials/nct05859750/), [A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer](https://onco.cc/trials/nct05235516/), [A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer](https://onco.cc/trials/nct05990127/), [A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepat](https://onco.cc/trials/nct06371157/), [A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct05142423/), [A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemor](https://onco.cc/trials/nct07010263/), [A Study of AK112 in Combination With VG2025 in Colorectal Cancer With Liver Metastases](https://onco.cc/trials/nct07357220/), [A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)](https://onco.cc/trials/nct06530251/), [A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer](https://onco.cc/trials/nct05382442/), [A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer](https://onco.cc/trials/nct05227664/), [A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer](https://onco.cc/trials/nct06938321/), [A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer](https://onco.cc/trials/nct07114315/), [A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07623356/), [A Study of Ivonescimab in First-Line ES-SCLC](https://onco.cc/trials/nct07245446/), [A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma](https://onco.cc/trials/nct04974398/), [A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia](https://onco.cc/trials/nct04980885/), [AK104 for Recurrent or Metastatic Vulvar Cancer](https://onco.cc/trials/nct05932212/), [AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer](https://onco.cc/trials/nct05904379/), [AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer](https://onco.cc/trials/nct06646055/), [AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer](https://onco.cc/trials/nct06951503/), [AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer](https://onco.cc/trials/nct06591520/), [AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer](https://onco.cc/trials/nct05840016/), [AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor](https://onco.cc/trials/nct07158840/), [AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC](https://onco.cc/trials/nct05247684/), [AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer](https://onco.cc/trials/nct06767527/), [AK129 Combination Therapy for Advanced Solid Tumors](https://onco.cc/trials/nct06943820/), [An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer](https://onco.cc/trials/nct06560112/), [Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer](https://onco.cc/trials/nct06686030/), [COMPASSION-16 / AK104-303](https://onco.cc/trials/compassion-16/), [ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)](https://onco.cc/trials/nct06951646/), [HARMONi-2](https://onco.cc/trials/harmoni-2/), [HARMONi-A](https://onco.cc/trials/harmoni-a/), [Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer](https://onco.cc/trials/nct06928389/), [Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer](https://onco.cc/trials/nct07412613/), [SCRT Followed by AK112 in pMMR/MSS Mid-low Rectal Cancer](https://onco.cc/trials/nct07162714/), [Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct05689853/)
- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/), [Nasopharyngeal carcinoma](https://onco.cc/cancers/nasopharyngeal/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [PD-L1-high non-small-cell lung cancer without a driver mutation](https://onco.cc/cancers/pdl1-high-nsclc/)
- technologies: [Bispecific ADC](https://onco.cc/technologies/bispecific-adc/)
- people: [Caicun Zhou](https://onco.cc/people/zhou-caicun/), [Michelle Xia (Xia Yu)](https://onco.cc/people/xia-michelle/), [Wenfeng Fang](https://onco.cc/people/fang-wenfeng/)
- bottlenecks: [Regulatory divergence between regions](https://onco.cc/bottlenecks/b-regulatory-fragmentation/), [Trials do not represent the people who get cancer](https://onco.cc/bottlenecks/b-trial-diversity/)
- key papers: [HARMONi-2: ivonescimab, a PD-1 x VEGF bispecific, beats pembrolizumab head-to-head in PD-L1-positive lung cancer](https://onco.cc/key-papers/paper-harmoni-2-lancet-2025/)
- institutions: [National Medical Products Administration / Center for Drug Evaluation](https://onco.cc/institutions/nmpa-cde/)

---
JSON: https://onco.cc/api/v1/entities/akeso.json